CBD for Sleep: Does It Help With Insomnia? (November 2026)

Reviewed by: Bryan Doner, MD, & Cannabidiol Life’s Medical Review Team

INTRODUCTION:

Find out what research on CBD for sleep shows. Recent placebo-controlled trials of CBD found gains on some sleep measures, such as deep plus REM sleep, and no difference on others.
Light oak bedside table with a closed book and a softly lit lamp beside a made bed at dusk

Table of Contents

Data as of October 23, 2026; trial data updated November 13, 2026

Does CBD help with sleep? Some trials of CBD (cannabidiol, a non-intoxicating cannabinoid from hemp) found sleep benefits; the evidence is mixed and low-certainty. Of 20 CBD trials in our table with no stated THC dose, 7 found a sleep benefit (4 of them on some measures but not others), 1 found less teeth grinding during sleep, and 12 found no difference. A 2025 meta-analysis of 6 trials found no significant sleep-quality effect for CBD-only products, while products with other cannabinoids, such as THC (the intoxicating cannabinoid), did better.

The FDA has not approved CBD for sleep. The FDA has approved only one drug that contains CBD: Epidiolex, a prescription medicine for seizures linked to Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in people 1 year of age and older.

Key takeaways

  • A 2026 Lancet Psychiatry review found low-certainty evidence that cannabinoids may lengthen sleep in insomnia, while an October 2026 Cochrane review of 9 insomnia trials (537 adults) found cannabis products may make little to no difference to sleep quality, with very low certainty.
  • A 2026 meta-analysis in adults with insomnia reported that CBD doses of 50 to 300 mg and CBN (cannabinol, another cannabinoid) doses of 20 to 100 mg improved sleep and that formulations with THC showed no significant improvement. Its abstract gives no number of studies or people and no effect sizes.
  • Recent placebo-controlled trials of CBD alone found gains on some sleep measures and no difference on others: in 30 adults with insomnia (2024), wrist-tracker sleep efficiency was better on CBD while insomnia severity did not differ from placebo; neither CBD dose beat placebo in 63 worriers (2026); and in a 125-adult insomnia trial (2025), CBD with terpenes raised tracker-measured deep plus REM sleep 1.3 percentage points.
  • ClinicalTrials.gov lists 23 CBD studies for a sleep condition; 1 of 8 completed ones has posted results (Evidence Tracker, October 23, 2026).
  • Safety: the risks studied include sleepiness, liver-enzyme rises and drug interactions, with the clearest figures from prescription seizure doses (FDA label); see the safety section below.

On this page: Research · Study table · Sleepiness · Sleep stages · Mechanism · CBD vs THC vs CBN · Doses in studies · By the numbers · Safety · Guidelines · Quality · Legal status · FAQ · Sources

What does research show about CBD and sleep?

Two 2026 reviews looked at cannabinoids for insomnia (Cochrane; Lancet Psychiatry). The Lancet Psychiatry review of 54 trials found low-certainty evidence that cannabinoids may lengthen sleep in insomnia, and the Cochrane review rated the insomnia evidence very low certainty. A third 2026 review, a meta-analysis of 10 trials (2,134 people) of cannabinoids of all kinds, not CBD alone, found insomnia severity scores 3.73 points lower and total sleep about 34 minutes longer than on placebo or melatonin; side effects, mostly mild dizziness and dry mouth, were 3.96 times as likely, and its authors called for larger, longer trials.

Further reviews and meta-analyses reported a benefit or a favorable signal. Those cited below and in later sections, as of November 13, 2026, are a selection, not a full list. The reviews that rated the evidence low or very low certainty or called it insufficient are cited in this section. The 2025 meta-analysis that found no significant sleep-quality effect for CBD-only products is cited at the top of this page. A fourth 2026 review was a meta-analysis of medical cannabis (CBD, CBN and THC, alone or combined) in adults with insomnia. It reported that CBD doses of 50 to 300 mg and CBN doses of 20 to 100 mg “were found to be safe and effective for improving sleep.” It also reported that CBD under 50 mg was effective only with CBN added, and that formulations with THC “did not show significant improvement in sleep.” Its abstract gives no number of studies or people and no effect sizes.

An earlier 2020 systematic review covered 14 preclinical (animal or lab) studies and 12 human studies of cannabinoid therapies, including THC and CBD. It said “promising preliminary evidence” gave reason for future randomized trials in insomnia and five other sleep conditions, and found “insufficient evidence to support routine clinical use” of cannabinoid therapies for any sleep disorder. This was because little research had been published and most studies had a moderate-to-high risk of bias. The NIH’s NCCIH cites this review. A 2020 meta-analysis covered 5 studies of cannabis-based products (219 adults with insomnia disorder). It pooled three non-randomized studies and found “a favourable effect of cannabinoids” on Pittsburgh Sleep Quality Index scores, a difference of 1.89 points at 4 weeks or less and 2.41 points at 8 weeks. Its two randomized trials tested THC and nabilone, a synthetic analogue of THC, and its abstract does not name the products in the pooled studies. It rated all five studies poor quality, calling these “possible signals for efficacy” that “do not reliably inform evidence-based practice.” Three narrative reviews of cannabinoids and sleep described possible benefits. A 2022 review said “some study outcomes have suggested cannabinoid utility in insomnia disorder and sleep apnea,” but that most studies were small, not rigorously controlled and at high risk of bias. A 2021 review of preclinical and human studies said the results “indicate a potential therapeutic role for cannabinoids in the management of some sleep disorders,” though much of the data came from small studies with biased assessment. A 2017 review said preliminary research “suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia,” and that research on cannabis and sleep “is in its infancy and has yielded mixed results.” None of the three gives a count of studies or people in its abstract.

CBD for insomnia and poor sleep: what placebo-controlled trials found

In a 2024 pilot trial of 30 adults with insomnia, wrist-tracker sleep efficiency was better on CBD, while insomnia severity did not differ between CBD and placebo. In 125 adults with insomnia, CBD with terpenes raised deep plus REM (dreaming) sleep 1.3 percentage points without changing total sleep (2025 trial). A 2023 systematic review of CBD for insomnia symptoms covered 34 studies of all designs: among those that ran statistical tests, 4 of 7 with CBD-predominant products and 12 of 16 with near-equal CBD and THC reported significant improvement. Two of the 34 focused on people with insomnia, and several used unvalidated sleep measures.

A 208-person trial ended in 2023 without published results, and a phase 3 trial planned for 519 people is under way, no longer recruiting (NCT05253417, NCT05840822, as of October 23, 2026).

CBD for anxiety and sleep

Two trials in anxious adults point in different directions: one reported better sleep and one found no difference. In a 2026 trial of 63 high trait worriers, neither CBD dose beat placebo on sleep; a 2024 phase 3 trial in 178 adults with anxiety disorders reported better sleep quality as a secondary outcome, though its abstract gave no sleep scores. A 2019 chart review covered 72 adults at a psychiatric clinic who were given CBD alongside their usual care, with no comparison group. Sleep scores improved within the first month in 48 (66.7%) “but fluctuated over time,” and anxiety scores fell in 57 (79.2%). Across studies, a 2025 scoping review of 29 studies of cannabinoids, particularly CBD, found about 45% reported gains in both anxiety and sleep, and said designs, products and doses differed too much for firm conclusions; a 2022 systematic review of 58 studies found CBD eased anxiety more than it changed sleep. See CBD for anxiety for anxiety results.

Sleep with pain, PTSD, MS and menopause

A 2022 review of 39 trials (5,100 people, mostly with chronic pain) found a small improvement in sleep with cannabinoids, including THC products. A 2017 National Academies committee report found “moderate evidence” that cannabinoids, mainly a THC-plus-CBD mouth spray, improve short-term sleep outcomes in people with sleep disturbance linked to sleep apnea, fibromyalgia, chronic pain or multiple sclerosis. “Moderate” is the committee’s middle rating, under which chance, bias and confounding “cannot be ruled out with reasonable confidence.” In records of 1,962 cancer patients in a state medical cannabis program (products with varied THC and CBD; no placebo group), sleep disturbance improved 1.87 points in the fifth taking the most CBD vs about 1.5 points at lower CBD doses (2026). A 2023 cancer supportive-care guideline covered 2 systematic reviews and 15 randomized trials of cannabis in people with cancer (its abstract does not specify the products). It reported that 6 of the 15 trials “suggested benefits,” five of them for sleep, and that no trial had sleep or mood as its main outcome. It said there was “no high-quality evidence to recommend the use of cannabis” for these symptoms. See CBD for pain for pain results. The 2026 Lancet Psychiatry review found no significant effect on PTSD symptoms, and no trial in our table tested CBD for sleep in PTSD.

For multiple sclerosis (MS), the published sleep results come from cannabis-based medicines that combine THC with CBD, not from CBD alone. In 66 people with MS nerve pain, sleep disturbance fell 2.5 points on a THC-plus-CBD mouth spray vs 0.8 points on placebo over 4 weeks (2005). In 57 people with MS, THC-dominant capsules showed no significant difference from placebo, with a trend toward getting to sleep more easily (2004). A 2026 meta-analysis of 25 studies (2,949 patients) found sleep disruption improved 15.75 points on a 0 to 100 scale from before to after treatment with the spray, and rated the certainty low to very low.

We also found registered studies in MS and menopause with no published sleep results yet; the menopause studies test hemp cannabinoid products for mood and anxiety (NCT07840924, NCT05269628, NCT06831916, NCT07393672, as of October 23, 2026).

Why results differ

Daily amounts varied (doses in studies), some products added THC, and sleep was measured by questionnaire (Insomnia Severity Index, ISI; Pittsburgh Sleep Quality Index, PSQI), wrist tracker (actigraphy) or sleep lab (polysomnography). Every published placebo-controlled trial of CBD alone with sleep as the main outcome in insomnia, poor sleep or worry had 125 people or fewer and ran 4 weeks or less.

How the evidence has changed: the earliest trial in our table (1981) gave 15 people with insomnia single doses on separate nights, without stated randomization, and found more sleep at the highest dose than on placebo. Placebo-controlled trials from 2024 to 2026 gave CBD nightly or on most nights for 2 to 4 weeks to 30 to 125 people with insomnia or worry and found gains on some measures, such as tracker-measured sleep efficiency and deep plus REM sleep, and no difference on others, including the main insomnia or sleep score in two of them. Trials added to our table on November 13, 2026 show a similar split: CBN improved sleep-disturbance scores in 1,020 adults (2024) and THC-containing mouth sprays improved sleep measures in two nerve-pain trials (2004, 2005), while five other trials of products with THC found no significant difference in sleep and a 12-person pilot found worse sleep ratings than placebo (2025). Of four CBD-alone trials in people with arthritis or knee surgery rather than insomnia (2022 to 2026), one found better self-rated sleep and three found no difference in sleep. A 2017 committee report found moderate evidence that cannabinoids, mainly a THC-plus-CBD mouth spray, improve short-term sleep in people with sleep disturbance linked to chronic pain, fibromyalgia, MS or sleep apnea. Later reviews found insufficient evidence for routine clinical use (2020) and gave low or very low certainty ratings (2026).

Human sleep trials of CBD, CBN and CBD+THC products in one table

Our CBD sleep table lists every randomized or placebo-controlled human trial in our review that measured sleep or a sleep disorder. Of the 40 trials, 15 found a benefit on at least one sleep measure, 1 found less teeth grinding during sleep, and 24 found no benefit.

Human sleep trials of CBD, CBN and CBD+THC products, as of November 13, 2026
Study Design People Product and daily amount Length Sleep result
CBD with no stated THC dose (20)
Gundugurti 2024 Phase 3 RCT 178, anxiety Amount not stated 15 weeks Better (secondary)
Gournay 2026 RCT 63, worriers 50 or 300 mg 2 weeks No difference
Wang 2025 Crossover RCT 125, insomnia 300 mg, terpenes 4 weeks Deep plus REM +1.3 points
Dujic 2025 Crossover RCT 64, high blood pressure 225-450 mg 5 weeks Quality unchanged; daytime sleepiness lower
Winkler 2025 RCT 180, students Full-spectrum oil, to 1 mg/kg 30 days No difference; oil had some THC
Mojoli 2025 RCT 45, knee osteoarthritis 45 mg, full-spectrum oil 60 days No difference
Mastrofini 2024 RCT 54, healthy 100 mg 12 weeks No difference
Walczyńska-Dragon 2024 RCT 60, teeth grinding 5% or 10% formulation, in mouth 30 days Bruxism index 51% lower on 10% (placebo unchanged); sleep quality not measured
Kisiolek 2023 RCT 28, healthy 50 mg 8 weeks One subscale better
Rudisill 2023 RCT 40, healthy 300 mg once 1 dose Sleepiness rose in both groups
Vela 2022 RCT 136, hand osteoarthritis or psoriatic arthritis 20-30 mg 12 weeks No difference
Haffar 2022 RCT 80, knee replacement Topical CBD 3 times a day, amount not stated 2 weeks No difference
de Almeida 2021 RCT 33, Parkinson RBD 75-300 mg 14 weeks No fewer RBD episodes
Lopez 2020 RCT 65, overweight 15 mg 6 weeks No difference
Linares 2018 Crossover RCT 27, healthy 300 mg once 1 night No change
Sideris 2026 Pilot RCT 36, double knee replacement 400 or 800 mg per dose, 4 doses around surgery Around surgery Self-rated sleep better, objective measures not (secondary; significance not stated in the abstract)
Narayan 2024 Pilot RCT 30, insomnia 150 mg oil 2 weeks Severity same; tracker efficiency better
Peters 2023 Pilot RCT 40, trained adults 70 mg plus CBG 3.5 days No difference
Saleska 2024 Randomized, no placebo 1,793, poor sleep 15 mg 4 weeks All improved; no difference vs melatonin
Carlini 1981 Randomization not stated 15, insomnia 40, 80 or 160 mg once 1 night each More sleep at 160 mg
CBN or CBN plus CBD (3)
Lavender 2026 Crossover RCT 20, insomnia 30 or 300 mg CBN once 1 night each Waking unchanged; faster onset at 300 mg
Kolobaric 2024 RCT 1,020, wanted better sleep 25, 50 or 100 mg CBN 4 weeks Sleep disturbance better at every dose; no difference vs melatonin
Bonn-Miller 2024 RCT 293, poor sleep 20 mg CBN, 0-100 mg CBD 7 nights Fewer awakenings (CBN); CBD added nothing
CBD with a stated THC dose (17)
Narayan 2025 Crossover RCT 20, healthy THC:CBD 1:1 or 1:16 5 visits No difference
Liu 2024 RCT 61, Parkinson ~192 mg CBD, 6.4 mg THC 2 weeks Sleep scores favored placebo
Silva 2024 RCT 60, autistic children CBD-rich extract, 9:1 CBD to THC, mg not stated 12 weeks No significant difference (parent interview)
Ried 2023 Crossover RCT 29, insomnia ~3-22.5 mg CBD, 2-15 mg THC 2 weeks Light sleep +21 minutes
Schnapp 2022 Crossover RCT 150, autistic children and teens Up to 10 mg/kg CBD, 0.5 mg/kg THC 12 weeks No difference on any parent-rated sleep measure
Walsh 2021 Crossover RCT 24, insomnia 10 mg THC, 0.5 mg CBD (or double) 2 weeks Insomnia score 5.1 lower
Abrams 2020 Crossover RCT 27, sickle cell pain Vaporized cannabis, 4.4% THC, 4.9% CBD, 3 times a day 5 days each No difference in sleep interference
Allsop 2014 RCT 51, cannabis withdrawal Up to 80 mg CBD, 86.4 mg THC (mouth spray) 6 days Less sleep difficulty than on placebo; difference not significant
Rog 2005 RCT 66, MS nerve pain ~24 mg CBD, ~26 mg THC (mouth spray) 4 weeks Sleep disturbance 2.5 points lower vs 0.8 on placebo
Berman 2004 Crossover RCT 48, nerve-injury pain 1:1 THC and CBD spray, or THC spray; amounts not stated 2 weeks each Sleep measures better
Vaney 2004 Crossover RCT 57, MS spasticity ~5-11 mg CBD, 15-30 mg THC 2 weeks No significant difference; trend for falling asleep
So-Ngern 2025 Placebo-controlled 26, systemic sclerosis ~3.2 mg CBD, 2.9 mg THC 4 weeks No significant difference vs placebo
Suraev 2026 Crossover pilot RCT 20, insomnia 200 mg CBD, 10 mg THC 1 night REM 34 minutes shorter
Kurlyandchik 2026 Pilot RCT 24, fibromyalgia Up to ~35 mg CBD, ~35 mg THC 16 weeks Sleep score fell 4.9 points vs 1.9 on placebo; difference not significant
Hausenblas 2025 Crossover pilot RCT 20, mild insomnia 10 mg CBD, 6 mg CBN, 3 mg THC 10 days Quality and symptoms better
Haney 2025 Pilot RCT 12, chemotherapy nerve pain Up to 300 mg CBD, 15 mg THC 8 weeks Sleep ratings worse than placebo
Nicholson 2004 Randomization not stated 8, healthy 5 or 15 mg CBD, equal THC 1 night Less deep sleep

Amounts in the table are what each study gave; see doses in studies below.

RCT = randomized controlled trial; RBD = REM sleep behavior disorder; MS = multiple sclerosis; ~ = calculated from the paper. Company-funded or company-run: Bonn-Miller 2024, Gundugurti 2024, Hausenblas 2025, Kolobaric 2024, Kurlyandchik 2026, Narayan 2024, Peters 2023, Saleska 2024, Schnapp 2022, Walsh 2021, Wang 2025. Funding is not stated in the abstracts of Allsop 2014, Berman 2004, Haffar 2022, Haney 2025, Rog 2005, Sideris 2026, Silva 2024, Vaney 2004 or Vela 2022.

Any stated THC dose, ratio or percentage puts a trial in the THC group. Four other trials that measured sleep (Wade 2004, Notcutt 2004, Parrella 2026 and Kruger 2026) are not in the table because their sleep results are not in the abstract or in free full text.

Does CBD make you sleepy or tired?

Studies differ by dose and by who took CBD. In Epidiolex trials in people with Lennox-Gastaut or Dravet syndrome taking prescription seizure doses (10 to 20 mg/kg a day), sleepiness affected 32% vs 11% on placebo (FDA label). In healthy adults, sleepiness rose in both groups after a single dose of CBD or placebo (2023). In 16 healthy men, a single 600 mg dose of CBD did not differ from placebo on sedation or any other rating, while 10 mg of THC caused sedation (2012). CBD caused no sedation in worriers (2026), did not impair next-day thinking in insomnia (2025), and daytime sleepiness was lower on CBD in 64 adults with high blood pressure (2025).

Can CBD make sleep worse? None of the 20 CBD trials in our table with no stated THC dose reported worse sleep on CBD, and a 2021 meta-analysis of 17 trials (1,479 people) found that approved cannabinoid medicines, CBD included, did not worsen sleep. In the Epidiolex seizure trials, the label lists insomnia or poor sleep in 11% at the lower dose (10 mg/kg a day) vs 4% on placebo, and a 2023 analysis of a global side-effect database found insomnia reported more often than expected with prescription CBD for seizures (reporting signal 1.6); such reports cannot show how often it happens. Among products with THC, a study of 8 healthy young adults given THC with CBD on single nights (randomization not stated) found less deep sleep, with more waking at the higher dose (2004), and in a 12-person pilot in women with chemotherapy nerve pain, sleep ratings over 8 weeks were worse on CBD-plus-THC capsules than on placebo (2025).

CBD and sleep stages: REM, deep sleep, sleep apnea and restless legs

Over 4 weeks, a CBD-terpene product raised tracker-measured deep plus REM sleep by 1.3 percentage points in 125 adults with insomnia (2025, above). A single dose of CBD did not change sleep stages in 27 healthy adults in a sleep lab (2018), and a single dose of a THC-plus-CBD oil cut REM sleep by about 34 minutes in 20 adults with insomnia (2026). In 33 people with Parkinson disease, CBD did not reduce REM sleep behavior disorder episodes (acting out dreams) over 14 weeks (2021).

ClinicalTrials.gov lists no CBD study for sleep apnea (tracker). A 2024 systematic review of 9 studies of cannabinoids for obstructive sleep apnea found that 8 reported statistically significant, positive results, including a lower apnea-hypopnea index and better self-rated daytime sleepiness. The products were THC-type, not CBD (dronabinol, a synthetic THC, in 7 studies and cannabis in 2). The studies lasted 1 to 6 weeks, and 70% to 80% of participants reported side effects. The American Academy of Sleep Medicine says cannabis products should not be used for sleep apnea, which needs a diagnosis (when to get help). No published trial in our review was designed to test CBD for restless legs; ClinicalTrials.gov lists 2 registered CBD studies for it (NCT07224932, NCT06863740). No study in our review tested CBD for sleep paralysis or sleepwalking.

How might CBD affect sleep?

The endocannabinoid system is the body’s network of cannabinoid receptors and the molecules that bind them. In cell studies, CBD acted on the serotonin 5-HT1A receptor (2005); no study in our review measured whether this affects sleep in people.

CBD vs THC vs CBN for sleep: what studies found

CBN (cannabinol) is another cannabinoid. Hemp and marijuana differ by THC content (legal status).

On CBD or THC for sleep, the insomnia trial with the clearest benefit, a 5.1-point lower insomnia score, tested a THC-dominant oil with very little CBD (2021), so its result applies to THC-dominant products rather than to CBD alone. Few sleep trials have tested the “entourage effect,” the idea that cannabis compounds work better together: the 2025 meta-analysis found products with other cannabinoids did better than CBD-only products, but it compared products rather than testing combinations, and in the 293-person CBN trial below, adding CBD did not help further. In a 2024 trial of 1,020 adults who wanted better sleep, CBN softgels of 25, 50 or 100 mg, taken before bed for 4 weeks, each improved sleep-disturbance scores more than placebo, and no dose differed from 4 mg of melatonin. In a 2024 trial of 293 poor sleepers, CBN gummies led to fewer night awakenings than placebo but missed their main sleep-quality goal. In a 2026 sleep-lab trial in insomnia, the higher CBN dose shortened the time to fall asleep, though neither dose reduced time awake.

What users report points both ways. In one app study of 409 people with insomnia, cannabis flower with more CBD was linked to greater relief than flower with more THC (2018; three authors worked for the app’s maker); in another of 991 people, every strain type was rated helpful, and indica strains were rated as easing insomnia 0.59 points more than CBD strains (2021). Neither had a placebo group.

Has CBD been compared with melatonin for sleep?

One trial has. In a 2024 trial of 1,793 adults with sleep problems, sleep scores improved in every group over 4 weeks and did not differ between CBD and melatonin (a sleep hormone) capsules. The trial had no placebo group, so part of the improvement may be a placebo effect.

No trial in our review tested the safety of combining CBD and melatonin, and a 2023 JAMA study found 22 of 25 melatonin gummies mislabeled (74% to 347% of label).

How much CBD for sleep? Doses, forms and timing in sleep studies

There is no official dose of CBD for sleep, and no study has established a sleep dose for a given person. In CBD-alone trials that gave a fixed daily amount, adults received 15 to 450 mg a day, and 300 mg a day or less where sleep was the main outcome (2024, 2020, 2024, 2026; 450 mg in a blood-pressure trial). One surgery trial gave four doses of 400 or 800 mg around the operation rather than a fixed daily amount (2026).

A 2022 systematic review of dosing covered 31 studies of products with THC, CBD or both: sleep improved in 7 of 19 randomized and 7 of 12 uncontrolled studies, with no significant difference between THC and CBD, and its authors said the studies differed too much to recommend a dose. A 2023 review of oral CBD at 400 mg a day or less found benefits across conditions were clearer at 300 mg a day or more, while effects on insomnia were more marginal and less consistent. These are the amounts researchers used in studies. They are not dosing advice.

Higher amounts quoted online as a CBD dosage for sleep come from seizure trials (FDA label) and abuse-potential testing (2017).

Forms of CBD in studies
How it was taken Time to peak blood level In our sleep table?
Oil under the tongue or capsule 0-4 hours across 24 studies (review); Epidiolex 2.5-5 hours, about 5-fold higher peak after a high-fat meal (label) Yes
Gummy No gummy-specific human study in our review Yes (CBN trial)
Inhaled Faster than by mouth (review); vaping lung injury cases reported through February 2020 were linked mainly to THC vapes (CDC) Yes (THC-plus-CBD cannabis, 2020 trial)
Topical Time to peak not reported in the trial’s abstract; one trial after knee replacement found no difference in sleep scores Yes (2022 trial)

Trials gave CBD 30 to 90 minutes before bed (2018, 2024, 2023); none measured how soon it affects sleep, so studies cannot yet say when to take CBD oil for sleep. On a CBD tincture for sleep, mL measures volume and mg measures CBD; the label’s mg per mL links them.

CBD for sleep by the numbers (October 2026)

Compiled by Cannabidiol Life, data as of October 23, 2026
Metric Value As of Source and exact query
Registered studies testing CBD for a sleep condition 23 (19 CBD alone or CBD-dominant; 4 with more THC) Oct 23, 2026 ClinicalTrials.gov search (41 records) plus a THC-product search; 23 kept after review
Completed studies with posted results 1 of 8 (12.5%): NCT05233761 Oct 23, 2026 Same search
People in completed randomized CBD-group trials 454 in 5 trials; 349 in the 3 without any THC arm Oct 23, 2026 Actual enrollment: NCT05233761, NCT05253417, NCT07840924, NCT03948074, NCT05041647
Phase 3 trials 1 of 23 (NCT05840822, 519 planned); 15 of 23 not yet completed Oct 23, 2026 Same search
CBD studies for sleep apnea or RBD 0 (all 8 cannabinoid sleep-apnea studies use dronabinol, a synthetic THC) Oct 23, 2026 Apnea and RBD searches
PubMed papers on cannabidiol and sleep or insomnia 572 (6.7% of 8,587 cannabidiol papers); 50 RCTs; 31 systematic reviews or meta-analyses Oct 23, 2026 PubMed search
PubMed papers per year (publication date) 4 in 2015, 36 in 2019, 94 in 2025 (+161.1% since 2019), 77 in 2026 so far Oct 23, 2026 Same search plus year[dp]
US monthly searches, last 12 months “cbd for sleep” 7,070 (53.3% below its January 2023 peak); “cbn for sleep” 4,131 (up 714.4% since 2019) Oct 23, 2026 Ahrefs Keywords Explorer, US

Registered-study counts show research activity; results come from the published trials in the study table.

Method: we searched ClinicalTrials.gov (API v2) and PubMed on October 23, 2026, and read every registry record. CBD-dominant products (THC below one-tenth of the CBD dose) count as CBD; Ahrefs volumes are estimates. PubMed’s publication-date search counts a paper in both its online and print year, so the yearly counts overlap and add up to more than the 572 total.

Cite this data: Cannabidiol Life, “CBD for Sleep by the numbers (October 2026),” cbdoilsandedibles.com, https://cbdoilsandedibles.com/health/cbd-for-sleep/, data as of 2026-10-23.

Is CBD safe for sleep? Side effects, drug interactions and who should avoid it

Talk to your doctor before using CBD, especially if you take any medicines or supplements, have liver problems, or have a health condition. In studies, CBD was generally well tolerated, but it can cause side effects such as sleepiness, diarrhea and changes in appetite, it can affect the liver, and it can interact with other medicines.

Side effects in trials

In Epidiolex trials at prescription seizure doses, sleepiness, decreased appetite and diarrhea were more common than on placebo (FDA label). Across 39 cannabinoid trials, including THC products, sleepiness, dry mouth, fatigue and nausea were each 6 to 10 percentage points more common than on placebo (2022 review). The NCCIH also lists mood changes.

Liver effects and other FDA safety concerns

At the same prescription seizure doses (10 to 20 mg/kg a day), liver enzymes rose above 3 times normal in 13% on Epidiolex vs 1% on placebo (FDA label). In a 2025 FDA-run trial of 201 healthy adults, 5.6% of those taking daily CBD had the same rise within 4 weeks, vs none on placebo. In laboratory animals, CBD harmed the male reproductive system (FDA).

Drug interactions

CBD can affect how other medicines work, which can cause serious side effects. Using CBD with alcohol or with medicines that cause drowsiness, such as some medicines for anxiety, panic, stress or sleep, raises the risk of sleepiness and injury. Ask your doctor or pharmacist before combining CBD with any medicine or supplement.

  • The Epidiolex label lists interactions through the liver enzymes CYP3A4 and CYP2C19 (FDA label).
  • In 18 adults, a CBD-dominant product that also contained THC raised blood levels of the sedative midazolam 56%, the heartburn drug omeprazole 207% and the blood-pressure drug losartan 77% (2023).
  • The blood thinner warfarin is among the drugs with the most reported interactions (2024 review).

Long-term use and drug tests

The FDA said in 2023 that it had not found adequate evidence to determine how much CBD can be consumed, and for how long, before causing harm. In a two-year UK registry study of 211 people prescribed medical cannabis for insomnia (mostly THC products; no comparison group; registry owned by the prescribing clinic), sleep-quality ratings on a 0 to 10 scale went from 2.46 to 5.14, and 17 people (8.06%) reported side effects (2026). Some CBD products contain THC, even when the label says they don’t. Using CBD can lead to a positive drug test: in a 2026 controlled study, at least one person in every group taking CBD oil with a little THC tested positive, as did one urine sample from the CBD-only group.

Older adults

Yale researchers wrote in 2026 that rigorous studies of cannabis or CBD for sleep in older adults are “virtually nonexistent,” and that aging changes drug handling and interactions (2026).

Who should avoid CBD

Do not use CBD if you are pregnant, planning a pregnancy or breastfeeding. The FDA strongly advises against using CBD, THC or marijuana in any form during pregnancy or while breastfeeding.

CBD products are not for children. Keep them out of reach of children and pets. If a child swallows a CBD or THC product, call Poison Control at 1-800-222-1222 or get medical care right away.

People with liver disease, and people taking interacting medicines, should avoid CBD unless their doctor agrees.

When to see a doctor or sleep specialist

Poor sleep that lasts, or possible sleep apnea, calls for a medical check; chronic insomnia has guideline care. If you are in crisis or thinking about harming yourself, call or text 988 to reach the 988 Suicide & Crisis Lifeline. In an emergency, call 911.

Sleep medicine guidelines: what comes first for insomnia

The American Academy of Sleep Medicine’s 2021 guideline strongly recommends cognitive behavioral therapy for insomnia (CBT-I) for chronic insomnia in adults. CBT-I is a structured program for sleep habits and thoughts. The American College of Physicians’ guideline names CBT-I as the first treatment and says sleep medicines can be considered with a clinician when CBT-I alone does not help. Do not stop, reduce or change any prescribed medicine or treatment without talking to the doctor who prescribed it.

How to check a CBD product’s quality

How to check a CBD product’s quality: read its certificate of analysis (COA) from an accredited third-party lab. See our guides to reading a COA and verifying the lab. Also check THC content (per-container limit), CBD per serving, and that the lab and batch match the product.

Labels are not always accurate: a 2025 study that tested 56 CBD gummy products found that 70% missed their labeled CBD amount by more than 10%, and 39% contained THC. A 2024 test of 202 US CBD products detected heavy metals in 44, residual solvents in 181 and pesticides in 30; only 1% to 3% of detections exceeded a regulatory limit (funded by Epidiolex maker Jazz Pharmaceuticals). No sleep trial in our review compared CBD gummies for sleep with other forms, or compared full-spectrum vs broad-spectrum vs pure CBD.

Is CBD legal? Federal law is changing. Under the 2018 Farm Bill definition, hemp (including hemp-derived CBD) is cannabis with no more than 0.3% delta-9 THC by dry weight, and it is not a controlled substance. A new federal definition applies in two steps (section 781 of Public Law 119-37, with start dates set by Public Law 119-103). Starting November 12, 2026, hemp products that contain cannabinoids the plant cannot produce naturally no longer count as hemp. Starting December 11, 2026, the rest of the definition applies. It counts total THC, including THCA, and a finished hemp product such as a CBD oil or gummy qualifies as hemp only if each container holds no more than 0.4 mg of total THC and similar cannabinoids, and contains no cannabinoids that were synthesized or manufactured outside the plant. Some full-spectrum CBD products contain more THC than that. State laws differ and can be stricter. This is general information, not legal advice.

Background: Congressional Research Service, IF13136.

Frequently asked questions

Does CBD do anything for sleep?

Some trials found sleep benefits, and most found no difference. Gains seen with CBD alone include more deep plus REM sleep (with terpenes), better tracker-measured sleep efficiency and lower daytime sleepiness. A 2026 Lancet Psychiatry review found cannabinoids may lengthen sleep in insomnia (low certainty); the October 2026 Cochrane review rated the evidence very low certainty, and a 2025 meta-analysis found no significant sleep-quality effect for CBD-only products, while products with other cannabinoids did better.

What should you look for in a CBD product for sleep?

No trial in our review compared forms or spectrums of CBD for sleep. Check for a recent COA from an accredited lab, the THC content and the CBD per serving; labels are not always accurate (quality).

Does a stronger CBD product work better for sleep?

Few trials compared CBD amounts. In 15 people with insomnia given single doses, people reported more sleep than on placebo at the highest of three doses (160 mg, 1981). In a 2026 trial of 63 worriers over 2 weeks, the higher of two CBD amounts did slightly better than the lower, though neither beat placebo, and adding more CBD to CBN gummies did not help in a 2024 trial. There is no official dose (doses in studies).

Is CBD oil good for insomnia?

Some insomnia trials found benefits and others did not. In a 2024 trial of 30 adults with insomnia given CBD oil under the tongue nightly for 2 weeks, wrist-tracker sleep efficiency was better on CBD, but insomnia severity did not fall more than on placebo. Other insomnia trials found more sleep at the highest of three single doses (15 people, 1981) and more deep plus REM sleep with terpenes over 4 weeks (125 people, 2025).

Is CBD habit-forming if you use it for sleep?

In a 2017 controlled study, high oral doses of CBD showed no signs of abuse potential, unlike marijuana. No trial has tested years of nightly use; the longest CBD-alone trials in our table that measured sleep ran 12 to 15 weeks.

The bottom line on CBD for sleep

Some trials of CBD found sleep benefits and others found none. Of the 20 CBD trials in our table with no stated THC dose, 7 found a sleep benefit, such as more deep plus REM sleep with terpenes, better tracker-measured sleep efficiency or lower daytime sleepiness (4 of them on some measures but not others), 1 found less teeth grinding during sleep, and 12 found no difference. The earliest positive result came from single doses (1981); recent placebo-controlled trials giving CBD nightly or on most nights for 2 to 4 weeks found gains on some measures and no difference on others. Insomnia reviews rate the evidence low to very low certainty, and sleep guidelines put CBT-I first.

Important safety and legal information

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have about a medical condition.

These statements have not been evaluated by the Food and Drug Administration. Hemp-derived CBD products are not intended to diagnose, treat, cure, or prevent any disease.

For side effects, drug interactions, who should avoid CBD and when to get help, see the safety section above.

How we researched this

We do not sell or recommend products on this page. Every study cited was checked at PubMed or the publisher. Figures from Cannabidiol Life’s Evidence Tracker show the date and source used. Sources were checked in October and November 2026; this page will be updated January 1, 2027, with re-run data. Cannabidiol Life’s research library holds 5,059 PubMed records. On November 13, 2026 our search of it found 433 papers on CBD, CBN or medical cannabis and sleep that were not yet in our review; we checked 93 of them at PubMed and added 23 studies that met this page’s rules, plus 4 reviews and analyses from our October research that this page had not yet cited. Later that day we added 10 more sources from our October research (9 reviews, guidelines and committee reports and 1 chart review), each of which reported a favorable result. They are a selection, not a full list of the reviews on this topic.

Sources

  1. Narayan AJ, Downey LA, Rose S, et al. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. J Clin Sleep Med. 2024;20(5):753-763. PMID 38174873. https://pubmed.ncbi.nlm.nih.gov/38174873/
  2. US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). FDA Q&A page. Content current as of 07/16/2024. https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
  3. Varela LB, Miño Zambrano JE, Maura Goncalves Costa B, et al. Medical cannabis for the treatment of insomnia. Cochrane Database Syst Rev. 2026;10(10):CD016216. PMID 42863850. https://pubmed.ncbi.nlm.nih.gov/42863850/
  4. Gournay LR, Ferretti ML, Dickens HB, et al. The effects of cannabidiol on sleep disturbances within a sample of high trait worriers: A double-blind, randomized placebo controlled trial. Exp Clin Psychopharmacol. 2026;34(2):163-174. PMID 41678223. https://pubmed.ncbi.nlm.nih.gov/41678223/
  5. Jazz Pharmaceuticals. EPIDIOLEX (cannabidiol) oral solution: Full Prescribing Information (revised 5/2026; Medication Guide revised 7/2025). DailyMed, National Library of Medicine, SPL version 35, published June 15, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec
  6. da Silva GHS, Barbosa EC, de Lima FR, et al. Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: A systematic review and meta-analysis of randomised studies. Sleep Med Rev. 2025;84:102156. PMID 40929927. https://pubmed.ncbi.nlm.nih.gov/40929927/
  7. Wilson J, Dobson O, Langcake A, et al. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2026;13(4):304-315. PMID 41856154. https://pubmed.ncbi.nlm.nih.gov/41856154/
  8. National Center for Complementary and Integrative Health (NCCIH), NIH. Sleep Disorders: In Depth. NCCIH web page. Last Updated: May 2024. https://www.nccih.nih.gov/health/sleep-disorders-in-depth
  9. Wang M, Faust M, Abbott S, et al. Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. J Clin Sleep Med. 2025;21(1):69-80. PMID 39167421. https://pubmed.ncbi.nlm.nih.gov/39167421/
  10. Kisiolek JN, Flores VA, Ramani A, et al. Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity. Nutrients. 2023;15(19):4173. PMID 37836465. https://pubmed.ncbi.nlm.nih.gov/37836465/
  11. Mastrofini GF, McFadden BA, Chandler AJ, et al. The effects of a brand-specific, hemp-derived cannabidiol product on physiological, biochemical, and psychometric outcomes in healthy adults: a double-blind, randomized clinical trial. J Int Soc Sports Nutr. 2024;21(1):2370430. PMID 38904150. https://pubmed.ncbi.nlm.nih.gov/38904150/
  12. Lopez HL, Cesareo KR, Raub B, et al. Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects. J Diet Suppl. 2020;17(5):561-586. PMID 32456572. https://pubmed.ncbi.nlm.nih.gov/32456572/
  13. Winkler A, Meis AC, Hermann C. Placebo effects in a RCT assessing 30 days of low dose Cannabidiol (CBD) treatment for psychological distress in stressed students at risk for depression. J Cannabis Res. 2025;7(1):98. PMID 41316488. https://pubmed.ncbi.nlm.nih.gov/41316488/
  14. Gundugurti PR, Banda N, Yadlapalli SSR, et al. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. Asian J Psychiatr. 2024;97:104073. PMID 38797087. https://pubmed.ncbi.nlm.nih.gov/38797087/
  15. AminiLari M, Wang L, Neumark S, et al. Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. Sleep. 2022;45(2):zsab234. PMID 34546363. https://pubmed.ncbi.nlm.nih.gov/34546363/
  16. Saleska JL, Bryant C, Kolobaric A, et al. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. J Am Nutr Assoc. 2024;43(1):1-11. PMID 37162192. https://pubmed.ncbi.nlm.nih.gov/37162192/
  17. Dujic G, Kumric M, Vrdoljak J, et al. Chronic Cannabidiol Administration Mitigates Excessive Daytime Sleepiness and Fatigue in Patients with Primary Hypertension: Insights from a Randomized Crossover Trial. Cannabis Cannabinoid Res. 2025;10(4):549-557. PMID 39187263. https://pubmed.ncbi.nlm.nih.gov/39187263/
  18. Walczyńska-Dragon K, Kurek-Górecka A, Niemczyk W, et al. Cannabidiol Intervention for Muscular Tension, Pain, and Sleep Bruxism Intensity-A Randomized, Double-Blind Clinical Trial. J Clin Med. 2024;13(5):1417. PMID 38592260. https://pubmed.ncbi.nlm.nih.gov/38592260/
  19. Rudisill TM, Innes KK, Wen S, et al. The effects of cannabidiol on subjective states, cognition, and psychomotor function in healthy adults: A randomized clinical trial. Fundam Clin Pharmacol. 2023;37(3):663-672. PMID 36625844. https://pubmed.ncbi.nlm.nih.gov/36625844/
  20. de Almeida CMO, Brito MMC, Bosaipo NB, et al. Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Mov Disord. 2021;36(7):1711-1715. PMID 33754375. https://pubmed.ncbi.nlm.nih.gov/33754375/
  21. Linares IMP, Guimaraes FS, Eckeli A, et al. No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Front Pharmacol. 2018;9:315. PMID 29674967. https://pubmed.ncbi.nlm.nih.gov/29674967/
  22. Peters EN, Yardley H, Harrison A, et al. A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). J Int Soc Sports Nutr. 2023;20(1):2280113. PMID 37947792. https://pubmed.ncbi.nlm.nih.gov/37947792/
  23. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981;21(S1):417S-427S. PMID 7028792. https://pubmed.ncbi.nlm.nih.gov/7028792/
  24. Lavender IG, Marshall NS, McCartney D, et al. Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial. J Sleep Res. 2026;35(4):e70284. PMID 41698831. https://pubmed.ncbi.nlm.nih.gov/41698831/
  25. Bonn-Miller MO, Feldner MT, Bynion TM, et al. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Exp Clin Psychopharmacol. 2024;32(3):277-284. PMID 37796540. https://pubmed.ncbi.nlm.nih.gov/37796540/
  26. Narayan AJ, Manning B, Aitken B, et al. Same-Day Sedative and Night-Time Sleep Effects Following Combined Cannabinoid Formulations: A Randomised-Controlled Trial. Clin Drug Investig. 2025;45(7):417-429. PMID 40542913. https://pubmed.ncbi.nlm.nih.gov/40542913/
  27. Liu Y, Bainbridge J, Sillau S, et al. Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson’s Disease: A Randomized Trial. Mov Disord. 2024;39(5):863-875. PMID 38487964. https://pubmed.ncbi.nlm.nih.gov/38487964/
  28. Ried K, Tamanna T, Matthews S, et al. Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. J Sleep Res. 2023;32(3):e13793. PMID 36539991. https://pubmed.ncbi.nlm.nih.gov/36539991/
  29. Schnapp A, Harel M, Cayam-Rand D, et al. A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ. Biomedicines. 2022;10(7):1685. PMID 35884990. https://pubmed.ncbi.nlm.nih.gov/35884990/
  30. Walsh JH, Maddison KJ, Rankin T, et al. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep. 2021;44(11):zsab149. PMID 34115851. https://pubmed.ncbi.nlm.nih.gov/34115851/
  31. So-Ngern A, Sripanichkulchai B, Mahakkanukrauh A, et al. Efficacy of Cannabis Oil in Improving Subjective Sleep Quality in Systemic Sclerosis: A Prospective Placebo-Controlled Study. Life (Basel). 2025;15(5):727. PMID 40430155. https://pubmed.ncbi.nlm.nih.gov/40430155/
  32. Suraev A, McGregor IS, McCartney D, et al. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. J Sleep Res. 2026;35(1):e70124. PMID 40631525. https://pubmed.ncbi.nlm.nih.gov/40631525/
  33. Hausenblas H, Hooper S, Lynch T. Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. Health Sci Rep. 2025;8(2):e70481. PMID 39980821. https://pubmed.ncbi.nlm.nih.gov/39980821/
  34. Nicholson AN, Turner C, Stone BM, et al. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24(3):305-13. PMID 15118485. https://pubmed.ncbi.nlm.nih.gov/15118485/
  35. Narayan AJ, Hayley AC, Rose S, et al. The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial. Psychopharmacology (Berl). 2025;242(2):297-308. PMID 39153080. https://pubmed.ncbi.nlm.nih.gov/39153080/
  36. Ramar K, Rosen IM, Kirsch DB, et al. Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement. J Clin Sleep Med. 2018;14(4):679-681. PMID 29609727. https://pubmed.ncbi.nlm.nih.gov/29609727/
  37. Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037-43. PMID 16258853. https://pubmed.ncbi.nlm.nih.gov/16258853/
  38. Babalonis S, Haney M, Malcolm RJ, et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend. 2017;172:9-13. PMID 28088032. https://pubmed.ncbi.nlm.nih.gov/28088032/
  39. Cohen PA, Avula B, Wang YH, et al. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA. 2023;329(16):1401-1402. PMID 37097362. https://pubmed.ncbi.nlm.nih.gov/37097362/
  40. Millar SA, Stone NL, Yates AS, et al. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol. 2018;9:1365. PMID 30534073. https://pubmed.ncbi.nlm.nih.gov/30534073/
  41. Florian J, Salcedo P, Burkhart K, et al. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Intern Med. 2025;185(9):1070-1078. PMID 40622698. https://pubmed.ncbi.nlm.nih.gov/40622698/
  42. US Food and Drug Administration. What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD. FDA Consumer Update. Content current as of 03/05/2020. https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis
  43. Bansal S, Zamarripa CA, Spindle TR, et al. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Clin Pharmacol Ther. 2023;114(3):693-703. PMID 37313955. https://pubmed.ncbi.nlm.nih.gov/37313955/
  44. Nachnani R, Knehans A, Neighbors JD, et al. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Front Pharmacol. 2024;15:1282831. PMID 38868665. https://pubmed.ncbi.nlm.nih.gov/38868665/
  45. Johnson ED, Kilgore MW, Stafford M, et al. Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. Cannabis Cannabinoid Res. 2025;10(6):710-718. PMID 40454463. https://pubmed.ncbi.nlm.nih.gov/40454463/
  46. Draghmeh K, Gupta P, Yaggi H, et al. Cannabis for sleep in older adults: use has outpaced the science. J Cannabis Res. 2026;8(1):104. PMID 42855715. https://pubmed.ncbi.nlm.nih.gov/42855715/
  47. Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255-262. PMID 33164742. https://pubmed.ncbi.nlm.nih.gov/33164742/
  48. Qaseem A, Kansagara D, Forciea MA, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125-33. PMID 27136449. https://pubmed.ncbi.nlm.nih.gov/27136449/
  49. Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy (In Focus IF13136, updated September 28, 2026). https://www.congress.gov/crs-product/IF13136
  50. Gidal BE, Vandrey R, Wallin C, Callan S, Sutton A, Saurer TB, et al. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Front Pharmacol. 2024;15:1335441. PMID 38562466. https://pubmed.ncbi.nlm.nih.gov/38562466/
  51. US Centers for Disease Control and Prevention. Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products. CDC archived web page, data as of February 18, 2020. https://archive.cdc.gov/www_cdc_gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html
  52. US Food and Drug Administration. FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward. FDA statement, January 26, 2023. https://www.fda.gov/news-events/press-announcements/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol
  53. Wolinsky D, Zamarripa CA, Spindle TR, Klausner M, Cone EJ, Winecker RE, et al. The acute and chronic pharmacokinetics and pharmacodynamics of oral cannabidiol with and without low doses of delta-9-tetrahydrocannabinol. J Anal Toxicol. 2026;50(1):bkaf075. PMID 40704705. https://pubmed.ncbi.nlm.nih.gov/40704705/
  54. Asim R, Azeem B, Wijdan SA, et al. Efficacy of cannabinoids for insomnia and sleep disturbance: A systematic review and meta-analysis of randomized controlled trials. Sleep Med. 2026;148:109193. PMID 42574897. https://pubmed.ncbi.nlm.nih.gov/42574897/
  55. Ranum RM, Whipple MO, Croghan I, et al. Use of Cannabidiol in the Management of Insomnia: A Systematic Review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID 36149724. https://pubmed.ncbi.nlm.nih.gov/36149724/
  56. Perez JG, LaMontagne LG, Garcia GA, et al. Cannabinoids for Anxiety and Sleep Disturbances: A Scoping Review. Med Cannabis Cannabinoids. 2025;8(1):219-237. PMID 41384242. https://pubmed.ncbi.nlm.nih.gov/41384242/
  57. Narayan AJ, Downey LA, Manning B, et al. Cannabinoid treatments for anxiety: A systematic review and consideration of the impact of sleep disturbance. Neurosci Biobehav Rev. 2022;143:104941. PMID 36370842. https://pubmed.ncbi.nlm.nih.gov/36370842/
  58. Reddy AC, Hampton JM, Park SJ, et al. The effects of tetrahydrocannabinol and cannabidiol on sleep in cancer patients. Clin Transl Oncol. 2026;28(4):1431-1443. PMID 41120744. https://pubmed.ncbi.nlm.nih.gov/41120744/
  59. Kleiner D, Horváth IL, Mátis D, et al. Nabiximols in Multiple Sclerosis: Beyond Spasticity-An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes. Med Sci (Basel). 2026;14(3):346. PMID 42506315. https://pubmed.ncbi.nlm.nih.gov/42506315/
  60. Mojoli A, Haider O, Fakih Y, et al. Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial – CANOA – cannabis for osteoarthritis. Front Pharmacol. 2025;16:1657065. PMID 41487518. https://pubmed.ncbi.nlm.nih.gov/41487518/
  61. Vela J, Dreyer L, Petersen KK, et al. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022;163(6):1206-1214. PMID 34510141. https://pubmed.ncbi.nlm.nih.gov/34510141/
  62. Haffar A, Khan IA, Abdelaal MS, et al. Topical Cannabidiol (CBD) After Total Knee Arthroplasty Does Not Decrease Pain or Opioid Use: A Prospective Randomized Double-Blinded Placebo-Controlled Trial. J Arthroplasty. 2022;37(9):1763-1770. PMID 35390457. https://pubmed.ncbi.nlm.nih.gov/35390457/
  63. Sideris A, Chan W, Liu J, et al. Effects of cannabidiol (CBD) oral solution in patients undergoing bilateral total knee arthroplasty: A randomized, controlled, parallel, triple blind, pilot study. J Pain. 2026;51:106477. PMID 42913966. https://pubmed.ncbi.nlm.nih.gov/42913966/
  64. Kolobaric A, Saleska J, Hewlings SJ, et al. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN™ for Improving Sleep. Pharmaceuticals (Basel). 2024;17(8):977. PMID 39204082. https://pubmed.ncbi.nlm.nih.gov/39204082/
  65. Silva EAD, Medeiros WMB, Santos JPMD, et al. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. Trends Psychiatry Psychother. 2024;46:e20210396. PMID 35617670. https://pubmed.ncbi.nlm.nih.gov/35617670/
  66. Abrams DI, Couey P, Dixit N, et al. Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(7):e2010874. PMID 32678452. https://pubmed.ncbi.nlm.nih.gov/32678452/
  67. Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71(3):281-91. PMID 24430917. https://pubmed.ncbi.nlm.nih.gov/24430917/
  68. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-9. PMID 16186518. https://pubmed.ncbi.nlm.nih.gov/16186518/
  69. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112(3):299-306. PMID 15561385. https://pubmed.ncbi.nlm.nih.gov/15561385/
  70. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10(4):417-24. PMID 15327040. https://pubmed.ncbi.nlm.nih.gov/15327040/
  71. Kurlyandchik I, Tiralongo E, Lauche R, et al. Feasibility, Safety and Preliminary Efficacy of 1:1 THC:CBD Cannabis Oil for Fibromyalgia Symptoms: Results From a Randomised, Double-Blind, Placebo-Controlled Pilot Trial. Pain Res Manag. 2026;2026(1):e7311235. PMID 42142029. https://pubmed.ncbi.nlm.nih.gov/42142029/
  72. Haney M, Choo TH, Tiersten A, et al. Oral Cannabis for Taxane-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Study. Cannabis Cannabinoid Res. 2025;10(5):631-639. PMID 40611810. https://pubmed.ncbi.nlm.nih.gov/40611810/
  73. Martin-Santos R, Crippa JA, Batalla A, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des. 2012;18(32):4966-79. PMID 22716148. https://pubmed.ncbi.nlm.nih.gov/22716148/
  74. Spanagel R, Bilbao A. Approved cannabinoids for medical purposes – Comparative systematic review and meta-analysis for sleep and appetite. Neuropharmacology. 2021;196:108680. PMID 34181977. https://pubmed.ncbi.nlm.nih.gov/34181977/
  75. Calapai F, Mannucci C, McQuain L, et al. Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase. Pharmaceuticals (Basel). 2023;16(10):1420. PMID 37895891. https://pubmed.ncbi.nlm.nih.gov/37895891/
  76. Vigil JM, Stith SS, Diviant JP, et al. Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions. Medicines (Basel). 2018;5(3):75. PMID 29997343. https://pubmed.ncbi.nlm.nih.gov/29997343/
  77. Kuhathasan N, Minuzzi L, MacKillop J, et al. The Use of Cannabinoids for Insomnia in Daily Life: Naturalistic Study. J Med Internet Res. 2021;23(10):e25730. PMID 34704957. https://pubmed.ncbi.nlm.nih.gov/34704957/
  78. Velzeboer R, Malas A, Boerkoel P, et al. Cannabis dosing and administration for sleep: a systematic review. Sleep. 2022;45(11):zsac218. Erratum in: Sleep. 2023;46(3):zsad008. PMID 36107800. https://pubmed.ncbi.nlm.nih.gov/36107800/
  79. Arnold JC, McCartney D, Suraev A, et al. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clin Transl Sci. 2023;16(1):10-30. PMID 36259271. https://pubmed.ncbi.nlm.nih.gov/36259271/
  80. Koye A, Erridge S, Clarke E, et al. UK Medical Cannabis Registry: A Two-Year Prospective Observational Cohort Study of Clinical Outcomes in Insomnia. Neuropsychopharmacol Rep. 2026;46(4):e70180. PMID 42935025. https://pubmed.ncbi.nlm.nih.gov/42935025/
  81. Begazo K, Laing K, Mineo A, et al. Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis. J Am Assoc Nurse Pract. 2026;38(11):888-900. PMID 42207928. https://pubmed.ncbi.nlm.nih.gov/42207928/
  82. Suraev AS, Marshall NS, Vandrey R, et al. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Med Rev. 2020;53:101339. PMID 32603954. https://pubmed.ncbi.nlm.nih.gov/32603954/
  83. Bhagavan C, Kung S, Doppen M, et al. Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis. CNS Drugs. 2020;34(12):1217-1228. PMID 33244728. https://pubmed.ncbi.nlm.nih.gov/33244728/
  84. Lavender I, McGregor IS, Suraev A, et al. Cannabinoids, Insomnia, and Other Sleep Disorders. Chest. 2022;162(2):452-465. PMID 35537535. https://pubmed.ncbi.nlm.nih.gov/35537535/
  85. Kaul M, Zee PC, Sahni AS. Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders. Neurotherapeutics. 2021;18(1):217-227. PMID 33580483. https://pubmed.ncbi.nlm.nih.gov/33580483/
  86. Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017;19(4):23. PMID 28349316. https://pubmed.ncbi.nlm.nih.gov/28349316/
  87. Shannon S, Lewis N, Lee H, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041. PMID 30624194. https://pubmed.ncbi.nlm.nih.gov/30624194/
  88. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Committee’s Conclusions. National Academies Press; January 2017. https://nap.nationalacademies.org/resource/24625/Cannabis_committee_conclusions.pdf
  89. De Feo G, Case AA, Crawford GB, et al. Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression. Support Care Cancer. 2023;31(3):176. PMID 36809575. https://pubmed.ncbi.nlm.nih.gov/36809575/
  90. Boylan PM, Santibañez M, Thomas J, et al. Cannabinoids for obstructive sleep apnea: A systematic review. Pharmacotherapy. 2024;44(11):880-891. PMID 39498540. https://pubmed.ncbi.nlm.nih.gov/39498540/

CBD health guides · CBD for anxiety · CBD for pain

DON'T BE SHY

Leave a Reply

Your email address will not be published. Required fields are marked *

Pattern of white dots.
Cannabidiol Life white menu logo

IMPORTANT DISCLAIMER: